Nicotinamide Mononucleotide Administration Prevents Doxorubicin-Induced Cardiotoxicity and Loss in Physical Activity in Mice.

Autor: Margier M; LGD SARL, 13880 Velaux, France., Kuehnemann C; Buck Institute for Research on Aging, Novato, CA 94945, USA., Hulo N; Nuvamid SA, 1260 Nyon, Switzerland., Morales J; Buck Institute for Research on Aging, Novato, CA 94945, USA., Ashok Kumaar PV; Buck Institute for Research on Aging, Novato, CA 94945, USA., Cros C; Nuvamid SA, 1260 Nyon, Switzerland., Cannelle H; Nuvamid SA, 1260 Nyon, Switzerland., Charmetant J; LGD SARL, 13880 Velaux, France., Verdin E; Buck Institute for Research on Aging, Novato, CA 94945, USA.; Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA., Canault M; LGD SARL, 13880 Velaux, France., Grozio A; Buck Institute for Research on Aging, Novato, CA 94945, USA.; Nuvamid SA, 1260 Nyon, Switzerland.
Jazyk: angličtina
Zdroj: Cells [Cells] 2022 Dec 27; Vol. 12 (1). Date of Electronic Publication: 2022 Dec 27.
DOI: 10.3390/cells12010108
Abstrakt: Doxorubicin (Doxo) is a widely used antineoplastic drug with limited clinical application due to its deleterious dose-related side effects. We investigated whether nicotinamide mononucleotide (NMN) could protect against Doxo-induced cardiotoxicity and physical dysfunction in vivo. To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic. In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection. In the chronic study, B6 mice received a cumulative dose of 20 mg/kg Doxo administered in fractionated doses for five days. NMN (500 mg/kg/day) was supplied in the mice's drinking water beginning five days before the first injection of Doxo and continuing for 60 days after. We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models. In addition, NMN protected against Doxo-induced cardiotoxicity and loss of physical function in acute and chronic studies, respectively. In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways. Overall, our results suggest that NMN could prevent Doxo-induced toxicity in heart and skeletal muscle.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje